Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00593008 · ClinicalTrials.gov registry record · Phase 1
Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT00593008: Clinical Trial Phase 1 study, sponsored by Massachusetts General Hospital.
NCT00593008 is a Phase 1 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00593008, a Phase 1 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this research study is to try to define the highest doses of temsirolimus and gemcitabine that can be used safely in combination to treat advanced pancreatic cancer. Gemcitabine is a standard chemotherapy used for the treatment of pancreatic cancer.
Interventions
- DRUG Gemcitabine
- DRUG Temsirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
Why NCT00593008 stopped before completion
NCT00593008 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT00593008 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00593008 about?
NCT00593008 is a clinical study titled "Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer". The purpose of this research study is to try to define the highest doses of temsirolimus and gemcitabine that can be used safely in combination to treat advanced pancreatic cancer. Gemcitabine is a standard chemotherapy used for the treatment of pancreatic cancer.
What is the current status of trial NCT00593008?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2007-10. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00593008?
The interventions under investigation include: Gemcitabine (DRUG), Temsirolimus (DRUG).
Who is sponsoring clinical trial NCT00593008?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00593008's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia